Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads
Mingzong Li, Zenon Konteatis, N. Nagaraja, Yue Chen, Shubao Zhou, Guangning Ma, Stefan Größ, Katya Marjon, Marc L. Hyer, Everton Mandley, Max Lein, Anil K. Padyana, Lei Jin, Shuilong Tong, Rachel Peters, Joshua Murtie, Jeremy Travins, Matthew C. I. Medeiros, Peng Liu, Victoria Frank, Evan T. Judd, Scott A. Biller, Kevin M. Marks, Zhihua Sui, Samuel K. Reznik
Abstract
Inhibition of the S-adenosyl methionine (SAM)-producing metabolic enzyme, methionine adenosyltransferase 2A (MAT2A), has received significant interest in the field of medicinal chemistry due to its implication as a synthetic lethal target in cancers with the deletion of the methylthioadenosine phosphorylase (MTAP) gene. Here, we report the identification of novel MAT2A inhibitors with distinct in vivo properties that may enhance their utility in treating patients. Following a high-throughput screening, we successfully applied the structure-based design lessons from our first-in-class MAT2A inhibitor, AG-270, to rapidly redesign and optimize our initial hit into two new lead compounds: a brain-penetrant compound, AGI-41998, and a potent, but limited brain-penetrant compound, AGI-43192. We hope that the identification and first disclosure of brain-penetrant MAT2A inhibitors will create new opportunities to explore the potential therapeutic effects of SAM modulation in the central nervous system (CNS).